Bristol Myers Squibb (BMY) Depreciation and Depletion (2009 - 2026)

Bristol Myers Squibb has disclosed Depreciation and Depletion across 18 years of filings, most recently posting $139.0 million for Q1 2026.

• In Q1 2026, Depreciation and Depletion fell 15.76% year-over-year to $139.0 million; the TTM figure through Mar 2026 stood at $595.0 million (down 9.98% YoY), while the FY2025 annual figure was $621.0 million, down 4.61% from the prior year.
• Depreciation and Depletion climbed to $139.0 million in Q1 2026, from $132.0 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for BMY reached as high as $169.0 million in Q4 2024 and fell as low as $132.0 million in Q4 2025.
• The 5-year median for Depreciation and Depletion is $153.0 million (2022), against an average of $153.5 million.
• Annual changes were most pronounced in 2022 — Depreciation and Depletion advanced 11.68% — and 2025, when it fell 21.89%.
• A 5-year view of Depreciation and Depletion shows it stood at $153.0 million in 2022, then increased by 6.54% to $163.0 million in 2023, then gained by 3.68% to $169.0 million in 2024, then slipped by 21.89% to $132.0 million in 2025, then gained by 5.3% to $139.0 million in 2026.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered $139.0 million, $132.0 million, and $159.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.